In the context of HCC and its current therapies, preclinical data from murine melanoma models have shown that PPT1 inhibition enhances the anti-tumor activity of immune checkpoint inhibition using an anti-PD-1 antibody (160). Here, PPT1 is linked to hepatocellular carcinoma.